Avis et décisions de la HAS
La recommandation relative à la prise en charge à titre dérogatoire de l’infliximab (REMICADE) dans le cadre d’une recommandation temporaire d’utilisation, ci-jointe, est adoptée.
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
rgzYhEtuJr3N8efa